SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Paul S. who wrote (858)6/3/1998 4:49:00 PM
From: alex ma  Read Replies (1) | Respond to of 1185
 
Nortran cancelled financing:

1. Share price is not reflecting value

2. Current cash will last for two years.

biz.yahoo.com



To: Paul S. who wrote (858)6/3/1998 4:50:00 PM
From: F. Jay Abella, III  Read Replies (1) | Respond to of 1185
 
Paul:

Yes indeed, financing cancelled.

The real believers, (SOROS for example) stand to make a nice buck in a very short while, as the market should perceive this as a positive step for NRT. Incidentally they have 9mm in the bank and do not need massive dilution at what are now historically low prices).

I can't even imagine how many shares are short now. The exit hole is only so big for covering.

FJA



To: Paul S. who wrote (858)6/3/1998 7:50:00 PM
From: Wisee  Read Replies (1) | Respond to of 1185
 
Paul,

I agree with Nortran's management not to further dilute the stock at these boxing day sale prices.

This also means that it's going to take a little longer to get onto the TSE.

Nice things happen to those that wait.

Wisee


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News